Global hiring for pharma, biotech and life sciences companies

Quick answers

The five questions life sciences leaders ask first.

Why life sciences companies employ across borders

Life sciences companies need specialised scientific, clinical, regulatory, commercial and operational talent across countries.

Trials follow patients. A study recruits across sites in ten or twenty countries, and each site needs monitoring from people who speak the language and can visit in person.

Regulators are national. Submissions, inspections and post approval commitments need staff who know the local agency, and certain safety roles must sit inside a defined region.

Manufacturing sits in specific hubs. Ireland, Singapore and Germany hold deep quality and manufacturing pools built around existing plants.

Specialist talent is scarce everywhere at once. Biostatisticians, pharmacovigilance scientists and bioinformaticians are hard to find in any one hub. India and Poland hold large pools with GxP experience.

Launch needs local medical presence. A launch in Japan, Germany or Brazil needs medical science liaisons in country, well before any entity decision.

The roles and where they sit

Each market links to its country guide.

Hiring routes compared

The routes differ on whether the role can be documented for an inspector, how it ends with the study, and whether IP and data are protected.

What a global life sciences hire actually costs

Illustrative planning figures only, not quoted rates and not statutory percentages for any country. Real numbers depend on the market, the salary and the ceilings that apply.

Worked example, illustrative only. A senior CRA in a European market on €60,000 gross, with a 24% contribution load and 3% in mandatory benefits, costs roughly €76,000. Add the EOR fee, GxP onboarding and site travel and you are planning around €86,000 fully loaded, plus a severance reserve if the study ends early.

The five traps that catch life sciences companies

These are the failures we get called in to fix. Some cost money. Some cost a finding.

1. GxP roles cannot start until the training record exists

Quality, regulatory and manufacturing staff work under GMP, GCP or GLP, and each framework requires that a person is qualified by education, training and experience for the task, with the training documented before they perform it. An inspector will ask for the record, the curriculum and the date against the first batch record or monitoring visit the person signed. A hire who starts without an approved training file is a finding waiting to happen. Employment has to line up with quality: role and reporting line fixed in the contract, the training plan issued before the start date, and a release step before any regulated activity. When the person moves to a new study, the record follows them.

2. Trial teams are built in many countries and dismantled when the study ends

A phase three study can employ CRAs, monitors and site coordinators across fifteen countries for four years, then end in a month at database lock. Each of those people has a contract under local law, and local law decides how it ends. Fixed term contracts help, but several countries limit how many times a fixed term can be renewed and convert the person to permanent status after that, which a study extension can trigger without anyone noticing. Open ended contracts carry notice, severance and in some markets a required justification for dismissal. Plan the demobilisation when you plan enrolment: contract type per country, notice periods, severance reserves, and whether the person can move to the next study.

3. Scientists have statutory inventor rights in several countries

In the United States an assignment clause settles ownership of what a scientist discovers at work. Several major research markets do not work that way. Germany's Employee Inventions Act requires the employee to report an invention in writing, gives the employer a fixed window to claim it, then obliges the employer to pay compensation based on the invention's value. Japan's Patent Act gives employee inventors a right to reasonable benefit even where the contract vests the invention in the company. The United Kingdom has a narrower rule for inventions of outstanding benefit to the employer. For a company whose value is its patents, a missed claiming step or an unpaid inventor surfaces at the next financing. Locally drafted contracts with a working claiming process are the fix.

4. Safety and clinical data decide who may see what, from where

Pharmacovigilance case data, trial datasets and patient level records are health data about identifiable people, the most protected category under GDPR and under health privacy rules elsewhere. Pseudonymisation does not take trial data outside the EU regime. Some safety roles have residency conditions: the qualified person for pharmacovigilance for an EU marketing authorisation must reside and operate in the EU or EEA. An offshore data manager or case processor in India or Poland can do the work, but only within a defined scope: which studies, which fields, which systems, under a lawful transfer mechanism, with access logged. Define that before the hire and put it in the contract, so an audit finds the control rather than a gap.

5. Field medical staff can create a taxable presence or breach promotion rules

Medical science liaisons are non promotional by design: they exchange scientific information with clinicians and do not sell. Two things go wrong. First, permanent establishment. An MSL who starts supporting the commercial team, discussing pricing or arranging supply can look like a dependent agent, which makes the company taxable in a country where it has no entity. Second, promotion rules. Most countries restrict how prescription medicines may be promoted, and several require pharmaceutical representatives to hold a local certification. An MSL who drifts into promotion is doing regulated work without the licence. Keep the role definition tight, train the person on the line between scientific exchange and promotion, and employ them locally so the record matches the role.

Where to hire, country by country

Every market below has a full country guide covering costs, payroll, leave and termination.

How Dryft works with life sciences companies

1. Map the study, not just the roles. Give us the countries, role families and expected duration. You get a modelled fully loaded cost per country with contract type and wind down terms flagged.
2. Pick the route per country. EOR for trial and launch teams, your own entity where a plant or affiliate is durable.
3. Align employment with quality. Role, reporting line and start date are fixed in the contract so your training record and release line up with day one.
4. Get inventions and data access right. Local terms carry the claiming procedure, assignment language and a scoped data access clause.
5. Onboard in days. Offer, contract, registrations, benefits and payroll setup run in parallel with your GxP training plan.
6. Run payroll monthly. Global payroll, contributions, filings, field expenses, one invoice.
7. Demobilise or redeploy cleanly. At study end we run notice, severance and exits under local rules, or move the person to the next study. Recruiting, immigration and managed teams use the same infrastructure.

FAQ

This guide is general information, not legal, tax, regulatory or immigration advice. Every cost figure here is an illustrative planning range, not a quoted rate for any country. GxP and regulatory obligations remain with the sponsor or marketing authorisation holder. Rules differ by jurisdiction and change regularly. Confirm the position for your countries with a qualified adviser before acting. Last reviewed September 2026.